<code id='0B6C986CBB'></code><style id='0B6C986CBB'></style>
      • <acronym id='0B6C986CBB'></acronym>
      <center id='0B6C986CBB'><center id='0B6C986CBB'><tfoot id='0B6C986CBB'></tfoot></center><abbr id='0B6C986CBB'><dir id='0B6C986CBB'><tfoot id='0B6C986CBB'></tfoot><noframes id='0B6C986CBB'>
      • <optgroup id='0B6C986CBB'><strike id='0B6C986CBB'><sup id='0B6C986CBB'></sup></strike><code id='0B6C986CBB'></code></optgroup>
        5. <b id='0B6C986CBB'><label id='0B6C986CBB'><select id='0B6C986CBB'><dt id='0B6C986CBB'><span id='0B6C986CBB'></span></dt></select></label></b><u id='0B6C986CBB'></u>
          <i id='0B6C986CBB'><strike id='0B6C986CBB'><tt id='0B6C986CBB'><pre id='0B6C986CBB'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / Wikipedia / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-28 04:40:44 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：knowledge   
                                        
                                      
                                      Page View：75
                                  
                                    
          
                                   
          Adobe
          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.
          The deal includes up to another $400 million in payments if certain milestones are met.
          advertisement
          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Pfizer plans to depart BIO
                                
                            
          Next article：  
                                      
                                          Walensky prepares to leave CDC — and Congress — behind
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles